Compare Mesoblast Limited (MESO) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Trip.com Group Ltd — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Trip.com Group Ltd trades at $43.65 (market cap $28.12B). The key difference: Trip.com Group Ltd is far larger — about 13× Mesoblast Limited's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TCOM | |
|---|---|---|
Market Cap | $2.17B | $28.12B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $78.96 |
52-Week Low | $12.88 | $39.84 |
Enterprise Value | $2.17B | $20.82B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TCOM trades at $44.15, up 4.0% over 24 hours but facing near-term pressure after recent earnings misses and regulatory scrutiny. The stock shows strong fundamentals with a P/E of 6.38 and net income margin of 48.65%, supported by robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Technical indicators signal a bearish trend with resistance at $44-$45, while analyst consensus remains bullish with a $56.72 price target despite recent guidance concerns.
The outlook balances high profitability and undervaluation against regulatory risks and slowing growth guidance. Investment appeal lies in its dominant market position and cash flow strength, but investors face headwinds from antitrust investigations and margin pressure. The stock's current discount to analyst targets presents opportunity if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
